WO2002005779A1 - Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin - Google Patents

Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin Download PDF

Info

Publication number
WO2002005779A1
WO2002005779A1 PCT/FR2001/001792 FR0101792W WO0205779A1 WO 2002005779 A1 WO2002005779 A1 WO 2002005779A1 FR 0101792 W FR0101792 W FR 0101792W WO 0205779 A1 WO0205779 A1 WO 0205779A1
Authority
WO
WIPO (PCT)
Prior art keywords
dhea
composition according
skin
chosen
composition
Prior art date
Application number
PCT/FR2001/001792
Other languages
French (fr)
Inventor
Roland Roguet
Guy Courchay
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Priority to AU2001267623A priority Critical patent/AU2001267623A1/en
Publication of WO2002005779A1 publication Critical patent/WO2002005779A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • A61K8/675Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00Manicure or pedicure preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/008Preparations for oily hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Definitions

  • composition in particular cosmetic, containing DHEA and / or its precursors or derivatives, and a vitamin
  • the present invention relates to a composition containing at least one compound chosen from DHEA and / or a biological precursor and / or a chemical or biological derivative thereof, and at least one vitamin chosen from vitamins B2, B3, B6 , B8, B12, D and K, as well as the use of said composition.
  • DHEA dehydroepiandrosterone
  • Exogenous DHEA administered topically or orally, is known for its ability to promote keratinization of the epidermis (JP-07 196 467) and to treat dry skin by increasing endogenous production and sebum secretion and by strengthening thus the barrier effect of the skin (US Pat. No. 4,496,556). It has also been described in US Pat. No. 5,843,932 the use of DHEA for remedying atrophy of the dermis by inhibiting the loss of collagen and connective tissue. It has also been described in US Pat. No. 5,736,537 the oral use of DHEA esters, in particular DHEA salicylate, for regulating the atrophy of the skin due to thinning or general degradation of the dermis.
  • a subject of the present invention is therefore a composition containing at least one compound chosen from DHEA and / or a biological precursor and / or a chemical or biological derivative thereof, characterized in that it also comprises at least one vitamin chosen from vitamins B2, B3, B6, B8, B12, D and K.
  • DHEA has the following formula (I):
  • DHEA biological precursors of DHEA is meant its precursors which are capable of transforming into DHEA during metabolism.
  • examples of such precursors are ⁇ 5-pregnenolone, 17 ⁇ -hydroxy pregnenolone and 17 ⁇ -hydroxy pregnenolone sulfate, without this list being limiting.
  • DHEA derivatives is understood to mean both its biological derivatives and its chemical derivatives.
  • biological derivatives there may be mentioned in particular ⁇ 5-androstene-3,17-diol and ⁇ 4-androstene-3,17-dione, without this list being limiting.
  • chemical derivatives mention may in particular be made of DHEA salts, in particular water-soluble salts, such as DHEA sulfate.
  • esters such as the esters of hydroxycarboxylic acids and of DHEA described in particular in US Pat. No. 5,736,537 or the other esters such as salicylate, acetate, valerate (or n-heptanoate) and enanthate of DHEA.
  • DHEA derivatives DHEA carbamates, DHEA 2-hydroxy malonate esters and DHEA amino acid esters
  • DHEA amino acid esters DHEA carbamates, DHEA 2-hydroxy malonate esters and DHEA amino acid esters
  • DHEA analogues The precursors and derivatives of DHEA will hereinafter be called "DHEA analogues”.
  • the concentration of DHEA and / or the like in the composition according to the invention is advantageously between 0.0001% and 10% by weight, preferably between 0.001% and 5% by weight, relative to the total weight of the composition.
  • composition according to the present invention contains, in combination with DHEA and / or its analogs, at least one vitamin chosen from vitamins B2, B3, B6, B8, B12, D and K.
  • Vitamin B2 riboflavin
  • Vitamin B3 niacinamide
  • Vitamin B6 pyridoxine
  • B8 biotin
  • vitamin B8 (or vitamin H) is particularly effective when combined with panthenol.
  • Vitamin B8 is also indicated in the treatment of brittle nails and, more generally, in the prevention of the integrity of the skin and integuments.
  • Vitamin B12 (cobalamin) contributes to the good condition of the skin.
  • Vitamin D (ergocalciferol) has also been shown to improve the differentiation of keratinocytes and prevent their hyper-proliferation.
  • vitamin K and in particular vitamin K1 (menadione) is notably known in the treatment of disorders of the blood vessels and photoaging (WO 95/11015).
  • DHEA and / or its analogues themselves have an activity on the signs of skin aging and in particular the atrophy of the epidermis, the pigment spots, the appearance papery of the skin, wrinkles, sagging skin and dull complexion.
  • the Applicant therefore believes, without wishing to be bound by this theory, that the combination of at least one of the above vitamins with DHEA or the like could advantageously improve the visual and / or tactile appearance of the skin and / or of its appendages and in particular to prevent or combat skin aging.
  • DHEA with at least one of vitamins B2, B6 and B8 could in particular make it possible to counter the hyper-seborrheic effect of DHEA applied to the skin, which may be undesirable in certain skin subjects oily, or prevent the formation of acneiform lesions in these same subjects, without harming the anti-aging properties of DHEA.
  • composition according to the invention can be in all dosage forms normally used for topical application to the skin, in particular in the form of an aqueous or oily solution, of an oil-in-water or water-in-oil emulsion or multiple, of a silicone emulsion, a microemulsion or nanoemulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product, an oil dispersion in an aqueous phase in the presence of spherules , these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or, better, lipid vesicles of ionic and / or nonionic type.
  • This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product. Alternatively, it can be in the form of a shampoo or conditioner.
  • the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matter.
  • the amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition.
  • These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or in nanoparticles.
  • These adjuvants, as well as their concentrations must be such that they do not harm the advantageous properties of the combination of active agents according to the invention.
  • the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
  • the fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
  • the emulsifier and the co-emulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
  • oils and in particular mineral oils such as mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin) can be used.
  • synthetic oils perhydrosqualene
  • silicone oils cyclomethicone
  • fluorinated oils perfluoropolyethers.
  • Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
  • emulsifiers and coemulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; fatty acid and polyol esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
  • fatty acid and polyethylene glycol esters such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate
  • fatty acid and polyol esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
  • hydrophilic gelling agents mention may be made in particular of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids and hydrophobic silica.
  • active agents depigmentants and keratolytic and / or scaling agents can be used in particular.
  • the active agents indicated above and / or the DHEA analogs according to the invention can be incorporated into spherules, in particular ionic or non-ionic vesicles and or nanoparticles (nanocapsules and / or nanospheres), so to isolate them from each other in the composition.
  • the - composition can be adapted for oral administration.
  • it can be in the form of syrups, suspensions, solutions, emulsions, capsules, granules or tablets, for example.
  • the daily doses of DHEA or analogues administered orally can be between 1 and 100 mg / day, preferably between 25 and 75 mg / day.
  • DHEA or the like is present in the composition according to the invention in an amount allowing its administration at a dose of between 50 and 100 mg / day, said dosage being carried out in one or more doses, with a unit dose of 50 mg. .
  • the daily doses of vitamins administered orally will preferably be included in the ranges indicated in Table 1 below:
  • composition according to the invention comprises an effective amount of DHEA or the like and of vitamin (s), sufficient to obtain the desired effect, and a physiologically acceptable medium.
  • composition according to the invention finds in particular an application in improving the visual and / or tactile appearance of the skin and / or its integuments and in particular in the prevention and treatment of the signs of skin aging.
  • the present invention therefore also relates to the cosmetic use of the composition mentioned above for improving the visual and / or tactile appearance of the skin and / or its integuments and in particular for preventing or treating the signs of skin aging.
  • the composition according to the invention is thus preferably used:
  • the present invention also relates to the cosmetic use of this composition for the treatment of the scalp and / or the hair and / or the nails.
  • Soft capsules are prepared, conventionally for those skilled in the art, having the following composition:
  • Soy lecithin 20 mg Natural tocopherols 5 mg
  • These capsules can be administered by taking a daily capsule.
  • Example 2 Composition for topical application
  • a treatment cream oil-in-water emulsion having the following composition is prepared, conventionally for a person skilled in the art:
  • Polysorbate 60 (Tween 60 ® sold by the company ICI) 1%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The invention concerns a composition containing DHEA and/or a biological precursor and/or chemical or biological derivative thereof, characterised in that it further comprises at least a vitamin selected among vitamins B2, B3, B6, B8, B12, D and K. The invention also concerns cosmetic and dermatological uses of said composition, in particular for preventing skin ageing symptoms.

Description

Composition, notamment cosmétique, renfermant la DHEA et/ou ses précurseurs ou dérivés, et une vitamine Composition, in particular cosmetic, containing DHEA and / or its precursors or derivatives, and a vitamin
La présente invention se rapporte à une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur biologique et/ou un dérivé chimique ou biologique de celle-ci, et au moins une vitamine choisie parmi les vitamines B2, B3, B6, B8, B12, D et K, ainsi qu'à l'utilisation de ladite composition.The present invention relates to a composition containing at least one compound chosen from DHEA and / or a biological precursor and / or a chemical or biological derivative thereof, and at least one vitamin chosen from vitamins B2, B3, B6 , B8, B12, D and K, as well as the use of said composition.
La DHEA, ou déhydroépiandrostérone, est un stéroïde naturel produit essentiellement par les glandes corticosurrénales. La DHEA exogène, administrée par voie topique ou orale, est connue pour sa capacité à promouvoir la kératinisation de l'épiderme (JP-07 196 467) et à traiter les peaux sèches en augmentant la production endogène et la sécrétion de sébum et en renforçant ainsi l'effet barrière de la peau (US-4,496,556). Il a également été décrit dans le brevet US-5,843,932 l'utilisation de la DHEA pour remédier à l'atrophie du derme par inhibition de la perte de collagène et de tissu conjonctif. Il a en outre été décrit dans le brevet US-5,736,537 l'utilisation par voie orale d'esters de DHEA, en particulier du salicylate de DHEA, pour réguler l'atrophie de la peau due à un amincissement ou une dégradation générale du derme.DHEA, or dehydroepiandrosterone, is a natural steroid produced primarily by the adrenal cortex. Exogenous DHEA, administered topically or orally, is known for its ability to promote keratinization of the epidermis (JP-07 196 467) and to treat dry skin by increasing endogenous production and sebum secretion and by strengthening thus the barrier effect of the skin (US Pat. No. 4,496,556). It has also been described in US Pat. No. 5,843,932 the use of DHEA for remedying atrophy of the dermis by inhibiting the loss of collagen and connective tissue. It has also been described in US Pat. No. 5,736,537 the oral use of DHEA esters, in particular DHEA salicylate, for regulating the atrophy of the skin due to thinning or general degradation of the dermis.
Or, il est apparu à la Demanderesse que l'association de la DHEA avec certaines vitamines pouvait permettre d'améliorer plus efficacement l'aspect visuel et/ou tactile de la peau et/ou des phanères et en particulier de prévenir ou traiter plus efficacement les signes de vieillissement cutané.However, it appeared to the Applicant that the combination of DHEA with certain vitamins could make it possible to improve more effectively the visual and / or tactile aspect of the skin and / or appendages and in particular to prevent or treat more effectively signs of skin aging.
La présente invention a donc pour objet une composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur biologique et/ou un dérivé chimique ou biologique de celle-ci, caractérisée en ce qu'elle comprend en outre au moins une vitamine choisie parmi les vitamines B2, B3, B6, B8, B12, D et K.A subject of the present invention is therefore a composition containing at least one compound chosen from DHEA and / or a biological precursor and / or a chemical or biological derivative thereof, characterized in that it also comprises at least one vitamin chosen from vitamins B2, B3, B6, B8, B12, D and K.
La DHEA a la formule (I) suivante :DHEA has the following formula (I):
Figure imgf000002_0001
Elle est par exemple disponible auprès de la société AKZO NOBEL.
Figure imgf000002_0001
It is for example available from the company AKZO NOBEL.
Par précurseurs biologiques de la DHEA, on entend ses précurseurs qui sont susceptibles de se transformer en DHEA au cours du métabolisme. Des exemples de tels précurseurs sont la Δ5-prégnénolone, la 17α-hydroxy prégnénolone et le sulfate de 17α-hydroxy prégnénolone, sans que cette liste soit limitative.By biological precursors of DHEA is meant its precursors which are capable of transforming into DHEA during metabolism. Examples of such precursors are Δ5-pregnenolone, 17α-hydroxy pregnenolone and 17α-hydroxy pregnenolone sulfate, without this list being limiting.
Par dérivés de la DHEA, on entend aussi bien ses dérivés biologiques que ses dérivés chimiques. Comme dérivés biologiques, on peut citer notamment le Δ5-androstène- 3,17-diol et la Δ4-androstène-3,17-dione, sans que cette liste soit limitative. Comme dérivés chimiques, on peut citer notamment les sels de DHEA, en particulier les sels hydrosolubles, tels que le sulfate de DHEA. On peut citer également les esters, tels que les esters d'acides hydroxycarboxyliques et de DHEA décrits notamment dans US-5,736,537 ou les autres esters tels que le salicylate, l'acétate, le valérate (ou n- heptanoate) et l'énanthate de DHEA. On peut également citer les dérivés de DHEA (carbamates de DHEA, esters de 2-hydroxy malonate de DHEA et esters d'amino- acides de DHEA) décrits dans la demande FR 00/03846 au nom de la Demanderesse. Cette liste n'est évidemment pas limitative.The term DHEA derivatives is understood to mean both its biological derivatives and its chemical derivatives. As biological derivatives, there may be mentioned in particular Δ5-androstene-3,17-diol and Δ4-androstene-3,17-dione, without this list being limiting. As chemical derivatives, mention may in particular be made of DHEA salts, in particular water-soluble salts, such as DHEA sulfate. Mention may also be made of esters, such as the esters of hydroxycarboxylic acids and of DHEA described in particular in US Pat. No. 5,736,537 or the other esters such as salicylate, acetate, valerate (or n-heptanoate) and enanthate of DHEA. Mention may also be made of the DHEA derivatives (DHEA carbamates, DHEA 2-hydroxy malonate esters and DHEA amino acid esters) described in application FR 00/03846 in the name of the Applicant. This list is obviously not exhaustive.
Les précurseurs et dérivés de DHEA seront dénommés ci-après "analogues de DHEA".The precursors and derivatives of DHEA will hereinafter be called "DHEA analogues".
La concentration en DHEA et/ou analogues dans la composition selon l'invention est avantageusement comprise entre 0,0001% et 10% en poids, de préférence entre 0,001% et 5% en poids, par rapport au poids total de la composition.The concentration of DHEA and / or the like in the composition according to the invention is advantageously between 0.0001% and 10% by weight, preferably between 0.001% and 5% by weight, relative to the total weight of the composition.
La composition selon la présente invention renferme, en association avec la DHEA et/ou ses analogues, au moins une vitamine choisie parmi les vitamines B2, B3, B6, B8, B12, D et K.The composition according to the present invention contains, in combination with DHEA and / or its analogs, at least one vitamin chosen from vitamins B2, B3, B6, B8, B12, D and K.
Les vitamines ci-dessus sont connues pour avoir des effets bénéfiques sur la peau ou ses phanères. Ainsi, la vitamine B2 (riboflavine) a été préconisée dans le traitement de l'acné rosacée et de la séborrhée, en raison de sa capacité à agir sur le renouvellement et l'entretien des tissus, de la peau et des muqueuses. Elle permet aussi de renforcer et tonifier la peau, les ongles et les cheveux. La vitamine B3 (niacinamide) a été largement décrite comme bénéfique contre les rugosités de la peau, et pour améliorer l'intégrité de la fonction barrière du stratum corneum, mais également comme anti-inflammatoire. Les vitamine B6 (pyridoxine) et B8 (biotine) sont connues comme anti-séborhéiques et utilisables, à ce titre, contre l'acné et les alopécies séborrhéiques. Dans cette dernière indication, la vitamine B8 (ou vitamine H) est particulièrement efficace lorsqu'elle est associée au panthénol. La vitamine B8 est également indiquée dans le traitement des ongles cassants et, d'une manière plus générale, dans la prévention de l'intégrité de la peau et des phanères. La vitamine B12 (cobalamine) participe au bon état de la peau. Il a en outre été montré que la vitamine D (ergocalciférol) améliorait la différenciation des kératinocytes et empêchait leur hyper-prolifération. Enfin, la vitamine K, et notamment la vitamine K1 (ménadione) est notamment connue dans le traitement des troubles des vaisseaux sanguins et du photovieillissement (WO 95/11015 ).The above vitamins are known to have beneficial effects on the skin or its appendages. Vitamin B2 (riboflavin) has been recommended in the treatment of acne rosacea and seborrhea, because of its ability to act on the renewal and maintenance of tissues, skin and mucous membranes. She permits also to strengthen and tone the skin, nails and hair. Vitamin B3 (niacinamide) has been widely described as beneficial against skin roughness, and for improving the integrity of the barrier function of the stratum corneum, but also as an anti-inflammatory. Vitamin B6 (pyridoxine) and B8 (biotin) are known as anti-seborheic and can be used, as such, against acne and seborrheic alopecia. In the latter indication, vitamin B8 (or vitamin H) is particularly effective when combined with panthenol. Vitamin B8 is also indicated in the treatment of brittle nails and, more generally, in the prevention of the integrity of the skin and integuments. Vitamin B12 (cobalamin) contributes to the good condition of the skin. Vitamin D (ergocalciferol) has also been shown to improve the differentiation of keratinocytes and prevent their hyper-proliferation. Finally, vitamin K, and in particular vitamin K1 (menadione) is notably known in the treatment of disorders of the blood vessels and photoaging (WO 95/11015).
Or, la Demanderesse a démontré que la DHEA et/ou ses analogues, appliqués par voie topique, ont eux-mêmes une activité sur les signes du vieillissement cutané et en particulier l'atrophie de l'épiderme, les taches pigmentaires, l'aspect papyracé de la peau, les rides, le relâchement cutané et le teint terne.However, the Applicant has demonstrated that DHEA and / or its analogues, applied topically, themselves have an activity on the signs of skin aging and in particular the atrophy of the epidermis, the pigment spots, the appearance papery of the skin, wrinkles, sagging skin and dull complexion.
La Demanderesse pense donc, sans vouloir être liée par cette théorie, que l'association de l'une au moins des vitamines ci-dessus avec la DHEA ou analogue pourrait avantageusement améliorer l'aspect visuel et/ou tactile de la peau et/ou de ses phanères et en particulier de prévenir ou lutter contre le vieillissement cutané.The Applicant therefore believes, without wishing to be bound by this theory, that the combination of at least one of the above vitamins with DHEA or the like could advantageously improve the visual and / or tactile appearance of the skin and / or of its appendages and in particular to prevent or combat skin aging.
Plus particulièrement, l'association de la DHEA à l'une au moins des vitamines B2, B6 et B8 pourrait notamment permettre de contrer l'effet hyper-séborrhéique de la DHEA appliquée sur la peau, qui peut être indésirable chez certains sujets à peau grasse, ou de prévenir la formation de lésions acnéiformes chez ces mêmes sujets, sans nuire pour autant aux propriétés anti-âge de la DHEA.More particularly, the combination of DHEA with at least one of vitamins B2, B6 and B8 could in particular make it possible to counter the hyper-seborrheic effect of DHEA applied to the skin, which may be undesirable in certain skin subjects oily, or prevent the formation of acneiform lesions in these same subjects, without harming the anti-aging properties of DHEA.
En outre, les effets de la vitamine B8 sur la prévention de la chute des cheveux permettent d'envisager l'association de cette vitamine avec la DHEA dans des produits capillaires où la DHEA trouve une application en raison de ses effets bénéfiques sur la canitie. In addition, the effects of vitamin B8 on preventing hair loss make it possible to consider the association of this vitamin with DHEA in products capillaries where DHEA finds an application because of its beneficial effects on canities.
L'homme du métier saura faire varier la quantité de vitamine(s) comprise dans la composition selon l'invention en fonction de l'effet recherché et des doses maximales admissibles compte tenu de la biodisponibilité de ces vitamines et de leurs éventuels effets indésirables.A person skilled in the art will know how to vary the amount of vitamin (s) included in the composition according to the invention as a function of the desired effect and of the maximum admissible doses taking into account the bioavailability of these vitamins and their possible undesirable effects.
La composition selon l'invention peut se présenter sous toutes les formes galéniques normalement utilisées pour une application topique sur la peau, notamment sous forme d'une solution aqueuse ou huileuse, d'une émulsion huile-dans-eau ou eau- dans-huile ou multiple, d'une émulsion siliconée, d'une microémulsion ou nanoémulsion, d'un gel aqueux ou huileux, d'un produit anhydre liquide, pâteux ou solide, d'une dispersion d'huile dans une phase aqueuse en présence de sphérules, ces sphérules pouvant être des nanoparticules polymériques telles que les nanosphères et les nanocapsules ou, mieux, des vésicules lipidiques de type ionique et/ou non-ionique.The composition according to the invention can be in all dosage forms normally used for topical application to the skin, in particular in the form of an aqueous or oily solution, of an oil-in-water or water-in-oil emulsion or multiple, of a silicone emulsion, a microemulsion or nanoemulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product, an oil dispersion in an aqueous phase in the presence of spherules , these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or, better, lipid vesicles of ionic and / or nonionic type.
Cette composition peut être plus ou moins fluide et avoir l'aspect d'une crème blanche ou colorée, d'une pommade, d'un lait, d'une lotion, d'un sérum, d'une pâte, d'une mousse ou d'un gel. Elle peut éventuellement être appliquée sur la peau sous forme d'aérosol. Elle peut également se présenter sous forme solide, et par exemple sous forme de stick. Elle peut être utilisée comme produit de soin et/ou comme produit de maquillage de la peau. En variante, elle peut se trouver sous la forme d'un shampooing ou après-shampooing.This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product. Alternatively, it can be in the form of a shampoo or conditioner.
De façon connue, la composition de l'invention peut contenir également les adjuvants habituels dans les domaines cosmétique et dermatologique, tels que les gélifiants hydrophiles ou lipophiles, les actifs hydrophiles ou lipophiles, les conservateurs, les antioxydants, les solvants, les parfums, les charges, les filtres, les pigments, les absorbeurs d'odeur et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans les domaines considérés, et par exemple de 0,01 à 20 % du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse, dans les vésicules lipidiques et/ou dans les nanoparticules. Ces adjuvants, ainsi que leurs concentrations, doivent être tels qu'ils ne nuisent pas aux propriétés avantageuses de l'association d'actifs selon l'invention.In a known manner, the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matter. The amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or in nanoparticles. These adjuvants, as well as their concentrations, must be such that they do not harm the advantageous properties of the combination of active agents according to the invention.
Lorsque la composition selon l'invention est une émulsion, la proportion de la phase grasse peut aller de 5 à 80 % en poids, et de préférence de 5 à 50 % en poids par rapport au poids total de la composition. Les matières grasses, les émulsionnants et les coémulsionnants utilisés dans la composition sous forme d'émulsion sont choisis parmi ceux classiquement utilisés dans le domaine considéré. L'émulsionnant et le co- émulsionnant sont de préférence présents, dans la composition, en une proportion allant de 0,3 à 30 % en poids, et de préférence de 0,5 à 20 % en poids par rapport au poids total de la composition.When the composition according to the invention is an emulsion, the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition. The fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration. The emulsifier and the co-emulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
Comme matières grasses utilisables dans l'invention, on peut utiliser les huiles et notamment les huiles minérales (huile de vaseline), les huiles d'origine végétale (huile d'avocat, huile de soja), les huiles d'origine animale (lanoline), les huiles de synthèse (perhydrosqualène), les huiles siliconées (cyclométhicone) et les huiles fluorées (perfluoropolyéthers). On peut aussi utiliser comme matières grasses des alcools gras tels que l'alcool cétylique, des acides gras, des cires et des gommes et en particulier les gommes de silicone.As fats which can be used in the invention, oils and in particular mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin) can be used. ), synthetic oils (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
Comme émulsionnants et coémulsionnants utilisables dans l'invention, on peut citer par exemple les esters d'acide gras et de polyéthylène glycol tels que le stéarate de PEG-100, le stéarate de PEG-50 et le stéarate de PEG-40 ; les esters d'acide gras et de polyol tels que le stéarate de glycéryle, le tristéarate de sorbitane et les stéarates de sorbitane oxyéthylénés disponibles sous les dénominations commerciales Tween® 20 ou Tween® 60, par exemple ; et leurs mélanges.As emulsifiers and coemulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; fatty acid and polyol esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
Comme gélifiants hydrophiles, on peut citer en particulier les polymères carboxyvinyliques (carbomer), les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylamides, les polysaccharides, les gommes naturelles et les argiles, et, comme gélifiants lipophiles, on peut citer les argiles modifiées comme les bentones, les sels métalliques d'acides gras et la silice hydrophobe. Comme actifs, on peut utiliser notamment les dépigmentants et les agents kératolytiques et/ou desquamants.As hydrophilic gelling agents, mention may be made in particular of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids and hydrophobic silica. As active agents, depigmentants and keratolytic and / or scaling agents can be used in particular.
En cas d'incompatibilité, les actifs indiqués cπdessus et/ou les analogues de DHEA selon l'invention peuvent être incorporés dans des sphérules, notamment des vésicules ioniques ou non-ioniques et ou des nanoparticules (nanocapsules et/ou nanosphères), de manière à les isoler les uns des autres dans la composition.In the event of incompatibility, the active agents indicated above and / or the DHEA analogs according to the invention can be incorporated into spherules, in particular ionic or non-ionic vesicles and or nanoparticles (nanocapsules and / or nanospheres), so to isolate them from each other in the composition.
Selon une variante de l'invention, la - composition peut être adaptée à une administration par voie orale. Dans ce cas, elle peut se présenter sous forme de sirops, de suspensions, de solutions, d'émulsions, de capsules, de granules ou de comprimés, par exemple.According to a variant of the invention, the - composition can be adapted for oral administration. In this case, it can be in the form of syrups, suspensions, solutions, emulsions, capsules, granules or tablets, for example.
Les doses quotidiennes de DHEA ou analogues administrées par voie orale peuvent être comprises entre 1 et 100 mg/jour, de préférence entre 25 et 75 mg/jour. Préférentiellement, la DHEA ou analogue est présente dans la composition selon l'invention en une quantité permettant son administration à une dose comprise entre 50 et 100 mg/jour, ladite posologie étant réalisée en une ou plusieurs prises, avec une dose unitaire de 50 mg.The daily doses of DHEA or analogues administered orally can be between 1 and 100 mg / day, preferably between 25 and 75 mg / day. Preferably, DHEA or the like is present in the composition according to the invention in an amount allowing its administration at a dose of between 50 and 100 mg / day, said dosage being carried out in one or more doses, with a unit dose of 50 mg. .
Les doses quotidiennes de vitamines administrées par voie orale seront de préférence comprises dans les gammes indiquées dans le Tableau 1 ci-après :The daily doses of vitamins administered orally will preferably be included in the ranges indicated in Table 1 below:
TABLEAU 1TABLE 1
Figure imgf000007_0001
Dans tous les cas, la composition selon l'invention comprend une quantité efficace de DHEA ou analogue et de vitamine(s), suffisante pour obtenir l'effet recherché, et un milieu physiologiquement acceptable.
Figure imgf000007_0001
In all cases, the composition according to the invention comprises an effective amount of DHEA or the like and of vitamin (s), sufficient to obtain the desired effect, and a physiologically acceptable medium.
La composition selon l'invention trouve en particulier une application dans l'amélioration de l'aspect visuel et/ou tactile de la peau et/ou de ses phanères et en particulier dans la prévention et le traitement des signes du vieillissement cutané.The composition according to the invention finds in particular an application in improving the visual and / or tactile appearance of the skin and / or its integuments and in particular in the prevention and treatment of the signs of skin aging.
La présente invention concerne donc- également l'utilisation cosmétique de la composition mentionnée ci-dessus pour améliorer l'aspect visuel et/ou tactile de la peau et/ou de ses phanères et en particulier pour prévenir ou traiter les signes du vieillissement cutané. La composition selon l'invention est ainsi de préférence utilisée :The present invention therefore also relates to the cosmetic use of the composition mentioned above for improving the visual and / or tactile appearance of the skin and / or its integuments and in particular for preventing or treating the signs of skin aging. The composition according to the invention is thus preferably used:
- pour prévenir ou réduire l'aspect papyracé de la peau, et/ou - pour améliorer l'homogénéité de la couleur de la peau et/ou pour blanchir la peau et/ou raviver l'éclat du teint, et/ou- to prevent or reduce the papery appearance of the skin, and / or - to improve the uniformity of the color of the skin and / or to whiten the skin and / or revive the radiance of the complexion, and / or
- pour traiter les rides et ridules, et/ou- to treat fine lines and wrinkles, and / or
- pour lutter contre le relâchement cutané, et/ou- to combat sagging skin, and / or
- pour lutter contre ou prévenir l'atrophie de l'épiderme.- to fight against or prevent atrophy of the epidermis.
La présente invention concerne également l'utilisation cosmétique de cette composition pour le traitement du cuir chevelu et/ou des cheveux et/ou des ongles.The present invention also relates to the cosmetic use of this composition for the treatment of the scalp and / or the hair and / or the nails.
L'invention sera maintenant illustrée par les exemples non limitatifs suivants. Dans ces exemples, les quantités sont indiquées en pourcentage pondéral.The invention will now be illustrated by the following nonlimiting examples. In these examples, the quantities are indicated in percentage by weight.
Exemple 1 - Composition pour administration oraleExample 1 Composition for Oral Administration
On prépare, de manière classique pour l'homme du métier, des capsules molles ayant la composition suivante :Soft capsules are prepared, conventionally for those skilled in the art, having the following composition:
Huile de soja hydrogénée 40 mgHydrogenated soybean oil 40 mg
Huile de blé 95 mgWheat oil 95 mg
Lécithine de soja : 20 mg Tocophérols naturels 5 mgSoy lecithin: 20 mg Natural tocopherols 5 mg
Acide ascorbique 30 mgAscorbic acid 30 mg
Vitamine D 5 μgVitamin D 5 μg
DHEA 50 mgDHEA 50 mg
Ces capsules peuvent être administrées à raison d'une prise quotidienne d'une capsule.These capsules can be administered by taking a daily capsule.
Exemple 2 -Composition pour application topiqueExample 2 -Composition for topical application
On prépare, de manière classique pour l'homme du métier, une crème de soin (émulsion huile dans eau) ayant la composition suivante :A treatment cream (oil-in-water emulsion) having the following composition is prepared, conventionally for a person skilled in the art:
Vitamine B3 1 % DHEA 0,1 %Vitamin B3 1% DHEA 0.1%
Stéarate de glycérol 2 %2% glycerol stearate
Polysorbate 60 (Tween 60 ® vendu par la société ICI) 1 %Polysorbate 60 (Tween 60 ® sold by the company ICI) 1%
Acide stearique 1 ,4 %Stearic acid 1, 4%
Triethanolamine 0,7 % Carbomer 0,4 %Triethanolamine 0.7% Carbomer 0.4%
Fraction liquide de beurre de karité 12 %Liquid fraction of shea butter 12%
Perhydrosqualène 12 %Perhydrosqualene 12%
Parfum 0,5 %Perfume 0.5%
Conservateur QS Eau QSP 100 % Preservative QS Water QSP 100%

Claims

REVENDICATIONS
1. Composition renfermant au moins un composé choisi parmi la DHEA et/ou un précurseur biologique et/ou un dérivé chimique ou biologique de celle-ci, caractérisée en ce qu'elle comprend en outre au moins une vitamine choisie parmi les vitamines B2, B3, B6, B8, B12, D et K.1. Composition containing at least one compound chosen from DHEA and / or a biological precursor and / or a chemical or biological derivative thereof, characterized in that it also comprises at least one vitamin chosen from vitamins B2, B3, B6, B8, B12, D and K.
2. Composition selon la revendication 1 , caractérisée en ce que ledit précurseur biologique de DHEA est choisi parmi : la Δ5-prégnénolone, la 17α-hydroxy prégnénolone et le sulfate de 17oc-hydroxy prégnénolone.2. Composition according to claim 1, characterized in that said biological precursor of DHEA is chosen from: Δ5-pregnenolone, 17α-hydroxy pregnenolone and 17oc-hydroxy pregnenolone sulfate.
3. Composition selon la revendication 1 ou 2, caractérisée en ce que ledit dérivé biologique de DHEA est choisi parmi : le Δ5-androstène-3,17-diol et la Δ4-androstène- 3,17-dione.3. Composition according to claim 1 or 2, characterized in that said biological derivative of DHEA is chosen from: Δ5-androstene-3,17-diol and Δ4-androstene-3,17-dione.
4. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit dérivé chimique de DHEA est choisi parmi : les sels de DHEA et les esters de DHEA.4. Composition according to any one of the preceding claims, characterized in that said chemical derivative of DHEA is chosen from: salts of DHEA and esters of DHEA.
5. Composition selon la revendication 4, caractérisée en ce que ledit sel de DHEA est choisi parmi les sels hydrosolubles, tels que le sulfate de DHEA.5. Composition according to claim 4, characterized in that said DHEA salt is chosen from water-soluble salts, such as DHEA sulfate.
6. Composition selon la revendication 4, caractérisée en ce que ledit ester de DHEA est choisi parmi : les esters d'acides hydroxycarboxyliques et de DHEA ; le salicylate de DHEA ; l'acétate de DHEA ; le valérate de DHEA ; et l'énanthate de DHEA.6. Composition according to claim 4, characterized in that said DHEA ester is chosen from: esters of hydroxycarboxylic acids and DHEA; DHEA salicylate; DHEA acetate; DHEA valerate; and DHEA enanthate.
7. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle renferme de 0,001 à 5% en poids de DHEA et/ou précurseur ou dérivé, par rapport au poids total de la composition.7. Composition according to any one of the preceding claims, characterized in that it contains from 0.001 to 5% by weight of DHEA and / or precursor or derivative, relative to the total weight of the composition.
8. Utilisation cosmétique de la composition selon l'une quelconque des revendications précédentes pour améliorer l'aspect visuel et/ou tactile de la peau et/ou de ses phanères. 8. Cosmetic use of the composition according to any one of the preceding claims for improving the visual and / or tactile appearance of the skin and / or its integuments.
9. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 7 pour prévenir ou traiter les signes du vieillissement cutané.9. Cosmetic use of the composition according to any one of claims 1 to 7 for preventing or treating the signs of skin aging.
10. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 7 pour prévenir ou réduire l'aspect papyracé de la peau et/ou pour améliorer l'homogénéité de la couleur de la peau et/ou pour blanchir la peau et/ou raviver l'éclat du teint, et/ou pour traiter les rides et ridules et/ou pour lutter contre le relâchement cutané, et/ou pour lutter contre ou prévenir l'atrophie de l'épiderme.10. Cosmetic use of the composition according to any one of claims 1 to 7 for preventing or reducing the papery appearance of the skin and / or for improving the uniformity of the color of the skin and / or for whitening the skin and / or revive the radiance of the complexion, and / or to treat fine lines and wrinkles and / or to combat sagging skin, and / or to combat or prevent atrophy of the epidermis.
11. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 7 pour le traitement du cuir chevelu et/ou des cheveux et/ou des ongles. 11. Cosmetic use of the composition according to any one of claims 1 to 7 for the treatment of the scalp and / or the hair and / or the nails.
REVENDICATIONS MODIFIEESAMENDED CLAIMS
[reçues par le Bureau international le 3 décembre 2001 (03.12.01); revendications originales 1-11 modifiées (2 pages)][received by the International Bureau on December 3, 2001 (03.12.01); original claims 1-11 amended (2 pages)]
1. Composition adaptée à être appliquée topiquement sur la peau, le cuir chevelu, les cheveux ou les ongles, renfermant (a) la DHEA et (b) au moins une vitamine choisie parmi les vitamines B2, B3, B6, B8 et B12.1. Composition adapted to be applied topically to the skin, scalp, hair or nails, containing (a) DHEA and (b) at least one vitamin chosen from vitamins B2, B3, B6, B8 and B12.
2. Composition renfermant (a) un précurseur biologique et/ou un dérivé chimique ou biologique de la DHEA, et (b) au moins une vitamine choisie parmi les vitamines B2, B3, B6, B8, B12, D et K.2. Composition containing (a) a biological precursor and / or a chemical or biological derivative of DHEA, and (b) at least one vitamin chosen from vitamins B2, B3, B6, B8, B12, D and K.
3. Composition selon la revendication 2, caractérisée en ce que ledit précurseur biologique de DHEA est choisi parmi la Δ5-prégnénolone, la 17α- hydroxy prégnénolone et le sulfate de 17α-hydroxy prégnénolone.3. Composition according to claim 2, characterized in that said biological precursor of DHEA is chosen from Δ5-pregnenolone, 17α-hydroxy pregnenolone and 17α-hydroxy pregnenolone sulfate.
4. Composition selon la revendication 2, caractérisée en ce que ledit dérivé biologique de DHEA est choisi parmi le Δ5-androstène-3,17-diol et la Δ4-androstène-3,17-dione.4. Composition according to claim 2, characterized in that said biological derivative of DHEA is chosen from Δ5-androstene-3,17-diol and Δ4-androstene-3,17-dione.
5. Composition selon la revendication 2, caractérisée en ce que ledit dérivé chimique de DHEA est choisi parmi les sels de DHEA et les esters de DHEA.5. Composition according to claim 2, characterized in that said chemical derivative of DHEA is chosen from DHEA salts and DHEA esters.
6. Composition selon la revendication 5, caractérisée en ce que ledit sel de DHEA est choisi parmi les sels hydrosolubles, tels que le sulfate de DHEA.6. Composition according to claim 5, characterized in that said DHEA salt is chosen from water-soluble salts, such as DHEA sulfate.
7. Composition selon la revendication 5, caractérisée en ce que ledit ester de DHEA est choisi parmi : les esters d'acides hydroxycarboxyliques et de DHEA ; le salicylate de DHEA ; l'acétate de DHEA ; le valérate de DHEA ; et l'énanthate de DHEA.7. Composition according to claim 5, characterized in that said DHEA ester is chosen from: esters of hydroxycarboxylic acids and DHEA; DHEA salicylate; DHEA acetate; DHEA valerate; and DHEA enanthate.
8. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle renferme de 0,001 à 5% en poids de DHEA et/ou précurseur ou dérivé, par rapport au poids total de la composition.8. Composition according to any one of the preceding claims, characterized in that it contains from 0.001 to 5% by weight of DHEA and / or precursor or derivative, relative to the total weight of the composition.
9. Utilisation cosmétique de la composition selon l'une quelconque des revendications précédentes pour améliorer l'aspect visuel et/ou tactile de la peau et/ou de ses phanères. 9. Cosmetic use of the composition according to any one of the preceding claims for improving the visual and / or tactile appearance of the skin and / or its integuments.
10. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 8 pour prévenir ou traiter les signes du vieillissement cutané.10. Cosmetic use of the composition according to any one of claims 1 to 8 for preventing or treating the signs of skin aging.
11. Utilisation cosmétique de la composition selon l'une quelconque des revendications 1 à 7 pour prévenir ou réduire l'aspect papyracé de la peau et/ou pour améliorer l'homogénéité de la couleur de la peau et/ou pour blanchir la peau et/ou pour raviver l'éclat du teint, et/ou pour traiter les rides et ridules et/ou pour lutter contre le relâchement cutané, et/ou pour lutter contre ou prévenir l'atrophie de l'épiderme. 11. Cosmetic use of the composition according to any one of claims 1 to 7 for preventing or reducing the papery appearance of the skin and / or for improving the uniformity of the color of the skin and / or for whitening the skin and / or to revive the radiance of the complexion, and / or to treat fine lines and wrinkles and / or to combat sagging skin, and / or to combat or prevent atrophy of the epidermis.
PCT/FR2001/001792 2000-07-13 2001-06-08 Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin WO2002005779A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001267623A AU2001267623A1 (en) 2000-07-13 2001-06-08 Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0009229A FR2811566B1 (en) 2000-07-13 2000-07-13 COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND A VITAMIN
FR00/09229 2000-07-13

Publications (1)

Publication Number Publication Date
WO2002005779A1 true WO2002005779A1 (en) 2002-01-24

Family

ID=8852491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/001792 WO2002005779A1 (en) 2000-07-13 2001-06-08 Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin

Country Status (3)

Country Link
AU (1) AU2001267623A1 (en)
FR (1) FR2811566B1 (en)
WO (1) WO2002005779A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1881836A1 (en) * 2005-05-06 2008-01-30 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
US20180168999A1 (en) * 2012-09-28 2018-06-21 Nutricos Technologies Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
US10105358B2 (en) 2013-05-09 2018-10-23 Zeenar Enterprises Pty Ltd Niacin formulation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510391A (en) * 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5883086A (en) * 1997-05-02 1999-03-16 Craft; John C. DHEA-containing nutritional supplement
EP0908183A1 (en) * 1997-10-08 1999-04-14 Institute For Advanced Skin Research Inc. Dehydroepiandrosterone or derivatives thereof for increasing the content of hyaluronic acid in skin
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
US5989568A (en) * 1995-01-26 1999-11-23 L'oreal Cosmetic/dermatological skin care compositions comprising S-DHEA
WO2000001351A1 (en) * 1998-07-07 2000-01-13 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
FR2792201A1 (en) * 1999-04-15 2000-10-20 Donatien Mavoungou Composition containing dehydroepiandrosterone, linoleic and stearic acids, for the treatment of acquired immune deficiency syndrome (AIDS) and leukemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510391A (en) * 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5989568A (en) * 1995-01-26 1999-11-23 L'oreal Cosmetic/dermatological skin care compositions comprising S-DHEA
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
US5883086A (en) * 1997-05-02 1999-03-16 Craft; John C. DHEA-containing nutritional supplement
EP0908183A1 (en) * 1997-10-08 1999-04-14 Institute For Advanced Skin Research Inc. Dehydroepiandrosterone or derivatives thereof for increasing the content of hyaluronic acid in skin
WO2000001351A1 (en) * 1998-07-07 2000-01-13 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
FR2792201A1 (en) * 1999-04-15 2000-10-20 Donatien Mavoungou Composition containing dehydroepiandrosterone, linoleic and stearic acids, for the treatment of acquired immune deficiency syndrome (AIDS) and leukemia

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1881836A1 (en) * 2005-05-06 2008-01-30 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
EP1881836A4 (en) * 2005-05-06 2009-11-25 Contech Entpr Inc Method for preparing and using water-based steroid pheromone compositions
US20180168999A1 (en) * 2012-09-28 2018-06-21 Nutricos Technologies Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
US11147302B2 (en) * 2012-09-28 2021-10-19 Nutricos Technologies Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails
US10105358B2 (en) 2013-05-09 2018-10-23 Zeenar Enterprises Pty Ltd Niacin formulation
US10335403B2 (en) 2013-05-09 2019-07-02 Zeenar Enterprise Pty Ltd Niacin formulation

Also Published As

Publication number Publication date
AU2001267623A1 (en) 2002-01-30
FR2811566B1 (en) 2003-01-17
FR2811566A1 (en) 2002-01-18

Similar Documents

Publication Publication Date Title
EP1064931B1 (en) Cosmetic composition containing at least one hydroxystilbene and ascorbic acid
EP0780115B1 (en) Nanoparticles coated with a lamellar phase based on a silicone surfactant and compositions containing them
EP1870081B1 (en) Use of ellagic acid for treating graying hair
EP0771557B1 (en) Use of ascorbic acid as the active agent for the treatment of seborrhea in a cosmetic and/or dermatalogical composition
EP1252882B1 (en) Process to increase the threshold tolerance of the sensitive skin
EP1269986B1 (en) Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, and corresponding uses and processes
FR2772612A1 (en) Cosmetic compositions for improving skin condition
FR2811561A1 (en) COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR A CHEMICAL OR BIOLOGICAL PRECURSOR OR DERIVATIVE THEREOF, AND A METALLOPROTEINASE INHIBITOR
EP1343459B1 (en) Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least one isoflavonoid
EP1172094B1 (en) Composition, particularly for cosmetics, comprising DHEA and/or precursor or derivative, and at least a compound which increases the synthesis of glycosaminoglycans
WO2002005778A1 (en) Composition, in particular cosmetic, comprising dhea and/or a precursor or derivative thereof, combined with at least a no-synthase inhibitor
FR2885050A1 (en) Slimming cosmetic and/or pharmaceutical composition, useful for treatment of adipocytes of skin, comprises cocoa extract containing polyphenols
EP1250121B1 (en) Use of dehydroepiandrosterone and/or precursors or derivatives thereof to improve papery aspect of the skin
EP1303253B1 (en) Composition, in particular cosmetic, comprising dhea and/or a precursor or derivative thereof, combined with at least a glycation inhibiting agent
WO2002005764A1 (en) Composition, in particular cosmetic, containing dhea and isoflavonoid
WO2002005779A1 (en) Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin
WO1999007337A1 (en) Use of a 2-amino-alkane polyol as agent for treating skin ageing signs
WO2002005776A1 (en) Composition, in particular cosmetic, containing dhea or some of its derivatives and a carotenoid
EP0940140A1 (en) Topical composition of alpha hydroxy acids and ceramides for the treatment of skin conditions
CA2511901A1 (en) Cosmetic composition for greasy skin care, containing a carboxylic fatty acid or a derivative thereof
WO2002047646A1 (en) Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a vitamin and/or an enzymatic cofactor
WO2002047648A1 (en) Composition, in particular cosmetic, comprising 7-hydroxy dhea and/or 7-keto dhea and at least an anti-glycation agent
FR2828400A1 (en) Cosmetic composition useful for improving skin condition comprises insulin-like growth factor or its mimetic and a retinoid
WO2002094212A1 (en) Cosmetic uses of 3-beta-acetoxy-7-oxo dhea
WO2002047655A1 (en) Composition, in particular cosmetic, comprising 7-hydroxy dhea or 7-keto dhea and at least a no-synthase inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP